The Cigna Group (NYSE:CI) Q4 2025 Earnings call February 05, 2026 08:30 AM ET Speaker11Ladies and gentlemen, thank you for standing by for The Cigna Group's fourth quarter 2025 results review. At this time, all callers are in a listen-only mode. We will conduct a question-and-answer session later during the conference and review procedures on how to inquire to ask questions at that time. If you should require assistance during the call, please press star zero on your touch-tone phone. As a reminder, ladies ...

Cigna (CI) came out with quarterly earnings of $8.08 per share, beating the Zacks Consensus Estimate of $7.87 per share. This compares to earnings of $6.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.70%. A quarter ago, it was expected that this health insurer would post earnings of $7.7 per share when it actually produced earnings of $7.83, delivering a surprise of +1.69%.Over the last four quarters, the company has su ...

Financial Performance - Total revenues for 2025 increased 11% to $274.9 billion compared to $247.1 billion in 2024[6] - Shareholders' net income for 2025 was $6.0 billion, or $22.18 per share, up from $3.4 billion, or $12.12 per share in 2024[4] - Adjusted income from operations for 2025 was $8.0 billion, or $29.84 per share, compared to $7.7 billion, or $27.33 per share in 2024[5] - Total revenues for the year ended December 31, 2025, reached $274,900 million, up from $247,121 million in 2024, marking an increase of 11.3%[39] - Shareholders' net income for Q4 2025 was $1,234 million, a decrease of 13.3% compared to $1,424 million in Q4 2024[40] - Adjusted income from operations for the year ended December 31, 2025, was $8,014 million, compared to $7,741 million in 2024, reflecting a growth of 3.5%[40] - The diluted earnings per share for the year ended December 31, 2025, was $22.18, up from $12.12 in 2024, indicating a significant increase of 83.9%[41] Customer Growth - Total customer relationships increased 3% to 188.4 million as of December 31, 2025, from 182.2 million in 2024[10] - Total pharmacy customers increased 4% to 123.6 million as of December 31, 2025, driven by new sales and expansion[10] - Total medical customers are projected to be approximately 18.1 million[25] Future Projections - 2026 adjusted income from operations is projected to be at least $7.950 billion, or at least $30.25 per share[6] - The Cigna Group projects full year 2026 adjusted revenues to be approximately $280.0 billion[24] - The consolidated adjusted income from operations for 2026 is expected to be at least $7.950 billion, equating to at least $30.25 per share[25] - The adjusted SG&A expense ratio is projected to be around 5.0% for 2026[25] - The adjusted effective tax rate is anticipated to be approximately 19.0%[25] - Cash flow from operations is expected to be around $9.0 billion for 2026[25] - Capital expenditures are projected to be approximately $1.3 billion[25] - Shareholder dividends for 2026 are expected to be around $1.6 billion[25] - Cigna Healthcare's adjusted income from operations is expected to be at least $4.5 billion for 2026[25] - Evernorth's adjusted income from operations is projected to be at least $6.9 billion for 2026[25] Operational Performance - Adjusted revenues for Evernorth Health Services increased 17% in Q4 2025 compared to Q4 2024, with adjusted income from operations increasing 2%[16] - Cigna Healthcare adjusted revenues decreased 16% in Q4 2025 compared to Q4 2024, primarily due to the impact of the HCSC transaction[19] - Pharmacy revenues increased to $58,336 million in Q4 2025 from $49,941 million in Q4 2024, representing a growth of 16.0%[39] - Adjusted revenues for Q4 2025 were $72,495 million, up from $65,683 million in Q4 2024, representing a growth of 12.8%[39] - Evernorth Health Services reported pre-tax adjusted income of $2,188 million in Q4 2025, slightly up from $2,146 million in Q4 2024[39] - Cigna Healthcare's pre-tax adjusted income increased to $734 million in Q4 2025 from $511 million in Q4 2024, a growth of 43.7%[39] Shareholder Information - The Board of Directors declared an increase in the quarterly dividend to $1.56 per share, up from $1.51 per share in 2025[6] - The company's shareholders' equity at December 31, 2025, was $41,713 million, compared to $41,033 million at the end of 2024, an increase of 1.7%[39] - The debt-to-capitalization ratio was 43.0% at December 31, 2025, down from 44.9% at September 30, 2025[8] - The weighted average shares outstanding decreased to 265,699 thousand in Q4 2025 from 277,784 thousand in Q4 2024, a decline of 4.3%[39]

Cigna Group logged higher revenue in its latest quarter as its pharmacy-benefit business Evernorth continues to grow. ...

Cigna on Thursday forecast 2026 profit and revenue below Wall Street expectations, signaling continued medical cost and margin pressure. ...

Core Insights - The Cigna Group reported strong financial results for 2025, highlighting operational discipline and a robust portfolio of global health businesses [1][2] - The company aims to build on its momentum in 2026, leveraging innovations and a diversified business model [2] Financial Performance - Shareholders' net income for Q4 2025 was $1.2 billion, or $4.64 per share, down from $1.4 billion, or $5.13 per share in Q4 2024 [2][3] - For the full year 2025, shareholders' net income reached $6.0 billion, or $22.18 per share, compared to $3.4 billion, or $12.12 per share in 2024 [3][6] - Adjusted income from operations for Q4 2025 was $2.1 billion, or $8.08 per share, up from $1.8 billion, or $6.64 per share in Q4 2024 [3][6] - Total revenues for 2025 increased by 11% to $274.9 billion, driven by growth in Evernorth Health Services [6][9] Customer Relationships - Total customer relationships increased by 3% to 188.4 million as of December 31, 2025, reflecting new sales and expansion in Pharmacy Benefit Services [8][15] - Total pharmacy customers rose by 4% to 123.6 million, while total medical customers decreased by 5% to 18.1 million, primarily due to the HCSC transaction [15][21] Segment Performance - Evernorth Health Services saw adjusted revenues increase by 16% and adjusted income from operations increase by 3% for the full year 2025 compared to 2024 [16][20] - Cigna Healthcare's adjusted revenues for 2025 were $47.2 billion, down from $52.9 billion in 2024, largely due to the divestiture of certain businesses [18][21] Outlook for 2026 - The Cigna Group projects adjusted revenues for 2026 to be approximately $280 billion, with adjusted income from operations expected to be at least $7.95 billion, or at least $30.25 per share [24][25] - The company anticipates a continued focus on operational efficiency, with an adjusted SG&A expense ratio projected to be around 5.0% [25]

Alexandria, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) --  The National Community Pharmacists Association cheered an announcement by the Federal Trade Commission today that insurance giant Cigna has agreed to make big concessions to help remedy years of unfair business practices that have plagued consumers with higher drug prices and hurt independent pharmacies by stifling competition. “This settlement will help lower consumers’ copays that have been tied to artificially inflated prices that feed Cigna’s insatiabl ...

Core Viewpoint - Cigna Corp's Express Scripts has reached a settlement with the U.S. Federal Trade Commission regarding claims that its insulin pricing practices violated antitrust and consumer protection laws, and has agreed to implement changes aimed at lowering insulin costs for consumers [1] Group 1: Settlement Details - The settlement addresses allegations of antitrust violations related to insulin pricing practices [1] - Changes agreed upon by Express Scripts are intended to reduce insulin costs for consumers [1] Group 2: Regulatory Context - The U.S. Federal Trade Commission's involvement highlights ongoing scrutiny of pharmaceutical pricing practices [1] - This settlement may set a precedent for future regulatory actions against similar pricing practices in the healthcare industry [1]

Core Insights - Cigna Corp's Express Scripts has settled claims from the U.S. Federal Trade Commission regarding antitrust violations in insulin pricing practices, agreeing to changes that aim to reduce costs for patients, insurers, and small pharmacies [1][2] Group 1: Settlement Details - The settlement aligns with the Trump administration's efforts to lower drug costs and allows the FTC to reduce a case initiated by the Biden administration against Express Scripts, UnitedHealth Group's Optum, and CVS Health's Caremark, with ongoing cases against Optum and Caremark [2] - The 10-year agreement restricts Express Scripts from engaging in practices that contribute to high costs, such as retaining rebate payments from drugmakers based on list prices, potentially saving patients up to $7 billion over the decade [4] - Express Scripts is now legally bound to comply with the settlement terms and will be monitored for three years [4] Group 2: Industry Context - Pharmacy benefit managers have faced scrutiny for pricing practices, with the FTC accusing them of directing patients and insurers towards higher-priced drugs to maximize profits [5] - The settlement requires Express Scripts to collaborate with local pharmacies and disclose drug costs to employers annually [5] - Cigna's insurance business primarily manages plans for employers, and the settlement mandates that direct-to-consumer drug purchases through the planned TrumpRX platform count towards copays and deductibles in standard employer plans [6] Group 3: Industry Trends - In recent years, CVS, UnitedHealth, and Cigna have introduced new pricing models aimed at increasing transparency regarding discounts, fees, and drug costs, shifting revenue models towards administrative fees rather than hidden reimbursements from drugmakers [7]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]